Portal de investigação
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Verdonschot, JAJ
- Pizard, A
- Pellicori, P
- La Rocca, HPB
- Clark, AL
- Cosmi, F
- Cuthbert, J
- Girerd, N
- Waring, OJ
- Henkens, MHTM
- Mariottoni, B
- Petutschnigg, J
- Rossignol, P
- Hazebroek, MR
- Cleland, JGF
- Zannad, F
- Heymans, SRB
- Ofhomage Heart Omics Ageing Consor
Unidades de investigação
Abstract
Background: Adipose tissue influences the expression and degradation of circulating biomarkers. We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone. Methods and Results: Protein biomarkers (n = 276) from the Olink Proseek Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline, 1 month and 9 months from the HOMAGE randomized controlled trial participants. Of the 510 participants, 299 had obesity defined as an increased waist circumference (>= 102 cm in men and >= 88 cm in women). Biomarkers at baseline reflected adipogenesis, increased vascularization, decreased fibrinolysis, and glucose intolerance in patients with obesity at baseline. Treatment with spironolactone had only minor effects on this proteomic profile. Obesity modified the effect of spironolactone on systolic blood pressure (P-interaction = 0.001), showing a stronger decrease of blood pressure in obese patients (-14.8 mm Hg 95% confidence interval -18.45 to -11.12) compared with nonobese patients (-3.6 mm Hg 95% confidence interval -7.82 to 0.66). Conclusions: Among patients at risk for heart failure, those with obesity have a characteristic proteomic profile reflecting adipogenesis and glucose intolerance. Spironolactone had only minor effects on this obesity-related proteomic profile, but obesity significantly modified the effect of spironolactone on systolic blood pressure.
Dados da publicação
- ISSN/ISSNe:
- 1071-9164, 1532-8414
- Tipo:
- Article
- Páginas:
- 778-786
- Link para outro recurso:
- www.scopus.com
Journal of Cardiac Failure Churchill Livingstone
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 3
Documentos
- Não há documentos
Filiações
Keywords
- Obesity; biomarker; heart failure; spironolactone
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Verdonschot J,Ferreira JP,Pizard A,Pellicori P,La Rocca HPB,Clark AL,Cosmi F,Cuthbert J,Girerd N,Waring OJ,Henkens MHTM,Mariottoni B,Petutschnigg J,Rossignol P,Hazebroek MR,Cleland JGF,Zannad F,Heymans SRB,Ofhomage Heart Omics Ageing C. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. J. Card. Fail. 2022. 28. (5):p. 778-786. IF:6,000. (1).
